6/17 With 164 members @wto leaks like the proverbial sieve
The Secretariat AND member governments are responsible for WTO info. But what is the division of labour? Are there biases? Secrecy and leaks arouse suspicion
7/17 Diverse audience: citizens, lawyers, academics, think-tankers, lobbyists, activists, journalists, politicians, business & industry associations, companies’ trade specialists. The media, NGOs are less interested now.
9/17 Public info is essential for public support. Secrecy arouses suspicion. Leaking worsens suspicion, and is biased. Leakers have an agenda. They leak to people who help push the agenda. Secretariat info is more neutral.
11/17 Small, private meetings are needed for real give-and-take. Otherwise negotiators go outside the WTO, even talking directly in capitals. They do already
The evidence is at best contradictory. There are two sides to this coin. One is legitimacy through public support. The other is negotiating efficiency, the ability to reach agreement.
16/17 Our proposals include: rethink WTO documents, more openness with agendas/minutes, members to make more negotiating proposals public, release all chairs’ draft texts, explain dispute rulings for a broader public.
…One minister insisted the draft mustn’t be released until approved. Next moment, delegates from that country were in the press room giving copies to favoured journalists…
Pfizer/BioNTech, Moderna mRNA vaccinations ongoing. J&J approved, not ordered. Supply picking up. Not yet approved: AstraZeneca, Curevac and Novavax. Switzerland has ordered over 30m doses for 8m people
Pfizer/BioNTech, Moderna mRNA vaccinations ongoing. J&J approved, not ordered. Supply picking up. Approval waiting: AstraZeneca, Curevac and Novavax. Switzerland has ordered over 30m doses for 8m people
Pfizer/BioNTech, Moderna mRNA vaccinations ongoing. Supply picking up. Still waiting for approval: AstraZeneca, Curevac and Novavax. Switzerland has ordered over 30m doses for 8m people
Pfizer/BioNTech, Moderna mRNA vaccinations ongoing. Supply picking up. Still waiting for approval: AstraZeneca, Curevac and Novavax. Switzerland has ordered over 30m doses for 8m people
2/10
Vaccinations and virus variants
“Fully” = second dose
Steady growth, deliveries up
Delivered: 2.1m=23.9% (from 1.7m)
Administered: 1.4m=17.8% (from 1.2m)
Fully: 577K=6.7% (from 507K)